Reprogrammed Interchange Llc Sells 447,278 Shares of Vor Biopharma (NYSE:VOR) Stock

Key Points

• Reprogrammed Interchange LLC sold 447,278 shares of Vor Biopharma stock at an average price of $1.54, totaling approximately $688,808, which represents a 1.35% decrease in their position.
• Vor Biopharma stock is currently down 15.2%, trading at $25.77, with significant fluctuations in average price over the past year, ranging from a low of $2.62 to a high of $65.80.
• Analysts have a moderate outlook on the stock, with an average rating of "Moderate Buy" and a price target averaging $121.33, reflecting a generally positive sentiment among market analysts.

Vor Biopharma Inc. (NYSE:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the firm's stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total transaction of $688,808.12. Following the completion of the transaction, the insider owned 32,781,209 shares in the company, valued at $50,483,061.86. This represents a 1.35% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company's stock are required to disclose their sales and purchases with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 22,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.80, for a total transaction of $688,780.40.
• On Monday, September 15th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $32.80, for a total transaction of $656,000.00.
• On Friday, September 12th, Reprogrammed Interchange Llc sold 15,000 shares of Vor Biopharma stock. The stock was sold at an average price of $35.00, for a total transaction of $525,000.00.
• On Thursday, September 11th, Reprogrammed Interchange Llc sold 14,240 shares of Vor Biopharma stock. The stock was sold at an average price of $36.60, for a total transaction of $521,184.00.
• On Monday, September 8th, Reprogrammed Interchange Llc sold 23,221 shares of Vor Biopharma stock. The stock was sold at an average price of $39.80, for a total transaction of $924,195.80.
• On Wednesday, September 10th, Reprogrammed Interchange Llc sold 17,500 shares of Vor Biopharma stock. The stock was sold at an average price of $36.40, for a total transaction of $637,000.00.
• On Tuesday, September 9th, Reprogrammed Interchange Llc sold 22,461 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total transaction of $898,440.00.
• On Friday, September 5th, Reprogrammed Interchange Llc sold 20,000 shares of Vor Biopharma stock. The stock was sold at an average price of $39.40, for a total transaction of $788,000.00.
• On Thursday, September 4th, Reprogrammed Interchange Llc sold 22,650 shares of Vor Biopharma stock. The stock was sold at an average price of $38.60, for a total value of $874,290.00.
• On Wednesday, September 3rd, Reprogrammed Interchange Llc sold 27,730 shares of Vor Biopharma stock. The stock was sold at an average price of $40.00, for a total value of $1,109,200.00.

Vor Biopharma Stock Performance

VOR stock traded up $0.69 on Monday, reaching $27.93. The company's stock had a trading volume of 264,474 shares, compared to its average volume of 379,843. The business has a fifty day simple moving average of $39.97 and a two-hundred day simple moving average of $22.99. Vor Biopharma Inc. has a 12-month low of $2.62 and a 12-month high of $65.80. The firm has a market cap of $176.91 million, a PE ratio of -16.93 and a beta of 2.05.

Hedge Funds Weigh In On Vor Biopharma

Several large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new position in shares of Vor Biopharma in the 1st quarter worth about $140,000. Two Sigma Investments LP raised its position in shares of Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock worth $181,000 after purchasing an additional 25,930 shares during the last quarter. Northern Trust Corp raised its position in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after purchasing an additional 44,252 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in shares of Vor Biopharma in the 1st quarter worth about $100,000. Finally, Goldman Sachs Group Inc. increased its holdings in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock worth $61,000 after buying an additional 58,247 shares in the last quarter. Hedge funds and other institutional investors own 97.29% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on VOR shares. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of Vor Biopharma in a research note on Thursday, August 14th. Wedbush reaffirmed an "outperform" rating on shares of Vor Biopharma in a research note on Thursday, June 26th. Five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $121.33.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.